8-K

                     U.S. SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                  --------------------------------------------


                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

         Date of Report (Date of earliest event reported) March 19, 2007
                                                          --------------


                                GREATBATCH, INC.
                                ----------------
             (Exact name of registrant as specified in its charter)



          Delaware                      1-16137                  16-1531026
- --------------------------------------------------------------------------------
(State or other jurisdiction of  (Commission File Number)      (IRS Employer
        incorporation)                                       Identification No.)



      9645 Wehrle Drive, Clarence, New York                        14031
- --------------------------------------------------------------------------------
     (Address of principal executive offices)                    (Zip Code)


        Registrant's telephone number, including area code (716) 759-5600
                                                           --------------


                                 Not Applicable
- --------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)

         Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425).

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240 14a-12).

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b)).

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-4(c)).





Item 8.01.   Other Events
             ------------

       On March 19, 2007, Greatbatch, Inc. (the "Company") issued a press
       release announcing that it has entered into a definitive agreement
       whereby the Company will acquire substantially all of the assets of
       BIOMEC, Inc. for $11.4 million in cash and future additional
       considerations. This agreement is subject to BIOMEC shareholder
       approval and will be funded with existing cash and short-term
       investments on hand.

       A copy of the release is furnished with this report as Exhibit 99.1.





Item 9.01.  Financial Statements and Exhibits
            ---------------------------------

       (d) Exhibits

       99.1 Press Release dated March 19, 2007.






                                   SIGNATURES

                  Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.


Dated:  March 19, 2007                       GREATBATCH, INC.

                                             By: /s/ Thomas J. Mazza
                                                 --------------------------
                                                 Thomas J. Mazza
                                                 Senior Vice President and
                                                 Chief Financial Officer










EXHIBIT               DESCRIPTION
NUMBER                -----------
- ------

99.1                  Press Release of Greatbatch, Inc. dated March 19, 2007.

EX-99.1

                                                                    EXHIBIT 99.1


       Greatbatch and BIOMEC Enter Into a Definitive Agreement


    CLARENCE, N.Y.--(BUSINESS WIRE)--March 19, 2007--Greatbatch, Inc.
(NYSE: GB) and BIOMEC, Inc. today announced that they have entered
into a definitive agreement whereby Greatbatch will acquire
substantially all of the assets of BIOMEC, Inc. for $11.4 million in
cash and future additional considerations. This agreement is subject
to BIOMEC shareholder approval.

    BIOMEC Inc. was established in 1998 with the objective of
accelerating promising technology from major medical and academic
institutions, national laboratories, and internal proprietary
developments to successful commercial products. BIOMEC operates in
Cleveland, OH and has built a highly effective engineering team with
diverse capabilities in medical device development that provides
creative solutions for customer's product development needs. In
collaboration with Dr. Roger Marchant, President of Nanomimetics Inc.
and Associate Professor of Biomedical Engineering and Director, Center
for Cardiovascular Biomaterials at Case Western Reserve University,
BIOMEC is developing a novel-polymer coating (biomimetic) that mimics
the surface of endothelial cells of blood vessels with potential use
on several medical devices, including in-dwelling central venous
catheters, cardiac pacing leads, and extra-corporeal blood pump
circuits in bypass surgery. Additionally, BIOMEC has a product
development and an investment partnership in IntElect Medical, an
early stage neurostimulation device company that works in conjunction
with the Cleveland Clinic.

    The acquisition will expand Greatbatch's ability to provide device
design and engineering services to its customers. It will also
accelerate internal efforts to integrate Greatbatch's components into
more complex device subsystems for its customers.

    Mauricio Arellano, Senior Vice President - Medical Solutions, for
Greatbatch stated, "We are very excited about this transaction. It is
a unique opportunity to advance our strategic intent to offer more
complete device design and engineering service capabilities. In
addition, BIOMEC is working on a number of proprietary technologies
and maintains strategic partnerships with several key early stage
device companies. We're specifically excited about a biomimetic
coating under development and expanding the strategic partnership it
has with IntElect Medical."

    About Greatbatch, Inc.

    Greatbatch, Inc. is a leading developer and manufacturer of
critical components used in implantable medical devices and other
technically demanding applications. Additional information about the
company is available at www.greatbatch.com.


    CONTACT: Investors:
             Greatbatch, Inc.
             Anthony W. Borowicz, 716-759-5809
             Treasurer and Director, Investor Relations
             tborowicz@greatbatch.com